<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872403</url>
  </required_header>
  <id_info>
    <org_study_id>FAH20120906</org_study_id>
    <secondary_id>FAHGuangzhou011</secondary_id>
    <nct_id>NCT01872403</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung</brief_title>
  <official_title>Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung
      squamous cell carcinoma has a better tumor response rate and safety, therefore.The main
      purpose of this study is to observe the safety and efficacy of albumin-bound paclitaxel /
      carboplatin in the treatment of lung squamous cell carcinoma of stage IIB and IIIA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung
      squamous cell carcinoma has a better tumor response rate and safety, therefore, this program
      is applied to neoadjuvant therapy, may obtain better tumor pathological remission rate,
      improve the operation resection rate, thus improve the prognosis.The main purpose of this
      study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the
      treatment of lung squamous cell carcinoma of stage IIB and IIIA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor ORR  and Number of Adverse Events</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 2 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of surgery until the date of first documented progression, assessed up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The rate of pathology down-stage of lymph nodes</measure>
    <time_frame>1 day (the date of surgery)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle albumin-bound paclitaxel/carboplatin</intervention_name>
    <description>Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:</description>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <other_name>paclitaxel /carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Histological or cytological diagnosis of lung squamous cell carcinoma of stage IIB and
        IIIA.

        2.18 years or older 3.ECOG Performance Status no more than 2; 4.Appraisable disease, the
        presence of at least three lesions if longest diameter &lt;10 mm by brain MRI; 5.Haemoglobin
        10.0 g/dl, Absolute neutrophil count (ANC) 1.5 x 10E9/L, platelets 100 x 10E9/L; 6.Total
        bilirubin 1.5 x upper limit of normal (ULN); 7.ALT and AST &lt; 2.5 x ULN in the absence of
        liver metastases, or &lt; 5 x ULN in case of liver metastases; 8.Creatinine clearance
        60ml/min (calculated according to Cockcroft-gault formula).

        Exclusion Criteria:

          1. Any systemic anticancer treatment for NSCLC

          2. Local radiotherapy for NSCLC.

          3. In this study within five years prior to the start of treatment with other than NSCLC
             patients with other cancers.

          4. Any instability in systemic disease, including: active infection, absence of control
             hypertension, unstable angina, begins in the last 3 months of angina pectoris,
             congestive heart failure

          5. HIV infection;

          6. Allergic to paclitaxel or Platinum;

          7. mixed with adenocarcinoma, small cell lung cancer;

          8. Pregnant or lactating women;

          9. Other researchers believe that does not fit into the group
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianxing he, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianxing he, MD</last_name>
    <phone>+86-02-83062808</phone>
    <email>hejx@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xinyun yang, master</last_name>
    <phone>+86-02-83062808</phone>
    <email>yxy701@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianxing HE, MD</last_name>
      <phone>+86-20-83062808</phone>
      <email>hejx@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>xinyun yang, master</last_name>
      <phone>+86-20-83062808</phone>
      <email>yxy701@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>jianxing he, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 6, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jianxing He</investigator_full_name>
    <investigator_title>The First Affiliated Hospital of Guangzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma of the lung</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
